Do Traders Think Cocrystal Pharma Inc (COCP) Can Turn Around Monday?

Cocrystal Pharma Inc (COCP) stock is down 7.19% over the past week and gets a Bearish rating from InvestorsObserver Sentiment Indicator.

Cocrystal Pharma Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on COCP!

See Full COCP Report

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With COCP Stock Today?

Cocrystal Pharma Inc (COCP) stock is up 1.77% while the S&P 500 has fallen -0.09% as of 10:17 AM on Monday, Apr 1. COCP is higher by $0.02 from the previous closing price of $1.40 on volume of 4,903 shares. Over the past year the S&P 500 has risen 27.28% while COCP has fallen -27.18%. COCP lost -$2.01 per share in the over the last 12 months. To screen for more stocks like Cocrystal Pharma Inc click here.

More About Cocrystal Pharma Inc

Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. The company employs structure-based technologies and Nobel Prize-winning expertise to create first-and best-in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). Click Here to get the full Stock Report for Cocrystal Pharma Inc stock.